SCHEMBL1979245

SCHEMBL1979245

CC(=O)Cc1ccc(F)cn1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.40
DAO P14920 1/20 0.40
AGBL2 Q5U5Z8 1/20 0.39
MBOAT4 Q96T53 1/20 0.37
SRC P12931 1/20 0.36
ADORA2A P29274 1/20 0.36
GABRA5 P31644 2/20 0.35
NTRK1 P04629 3/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
APLNR P35414 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ACACB O00763 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12984381 0.82 AGBL2 (0.47) RAB9ADAOAGBL2SRCGABRA5
SCHEMBL29535595 0.82 AGBL2 (0.47) RAB9ADAOAGBL2SRCGABRA5
SCHEMBL26803733 0.81 DAO (0.44) DAOAGBL2ADORA2AGABRA5HTR2A
SCHEMBL21909136 0.81 RAB9A (0.40) RAB9ADAOAGBL2MBOAT4SRC
SCHEMBL12986732 0.81 RAB9A (0.40) RAB9ADAOAGBL2MBOAT4SRC
SCHEMBL24086542 0.80 RAB9A (0.37) RAB9ADAOAGBL2MBOAT4SRC
SCHEMBL15174174 0.80 TYK2 (0.43) RAB9ADAOADORA2AL3MBTL1
SCHEMBL11099285 0.80 ESR1 (0.49)
SCHEMBL15174151 0.80 MTNR1A (0.39) RAB9ADAOADORA2AGABRA5NTRK1
SCHEMBL161772 0.79 CA1 (0.39) RAB9ADAOAGBL2MBOAT4SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737463-B2 Pyridine and pyrazine compounds BASF SE (DE) 2023-08-29 US disclosed
WO-2020064009-A1 SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 北京志健金瑞生物医药科技有限公司 2020-04-02 WO disclosed
WO-2015143340-A1 COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2015-09-24 WO disclosed
US-8841331-B2 Inhibitors of human immunodeficiency virus replication GILEAD SCIENCES, INC. (US) 2014-09-23 US disclosed
WO-2011072064-A1 S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 WO disclosed
US-20110071289-A1 AMINOPYRAZOLE AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737463-B2 Pyridine and pyrazine compounds NDUFS5, IL5, NDUFS4 RAB9A 3644/4885DAO 2627/4885AGBL2 4454/4885
US-20110071289-A1 AMINOPYRAZOLE AMIDE DERIVATIVE ARGLU1, ARG1, CNKSR1 RAB9A 470/4885DAO 414/4885AGBL2 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.